Patient-Reported Outcomes After Treatment With OnabotulinumtoxinA for Platysma Prominence: Results From a Phase 2 Dose-Ranging Study
Quick Take
OnabotulinumtoxinA demonstrates a dose-dependent signal for improved patient-reported outcomes (PROs) in treating platysma prominence. While promising, Phase 2 results require validation in larger, long-term trials.
š” Clinical Impact
- Mechanistic Why: Selective chemodenervation of hyperactive platysma muscle fibers reduces the appearance of vertical bands and improves cervicomental definition.
- Clinical/Systemic Benefit: Offers a viable non-surgical alternative for patients with mild-to-moderate neck aging, prioritizing patient-centric satisfaction with significantly lower downtime compared to surgical platysmaplasty.
š Evidence Breakdown
Evidence Grade: š” 7/10 (Early-Phase Exploratory RCT)
Analysis: The study establishes a clear dose-response relationship, which is critical for validating pharmacological efficacy. However, as a Phase 2 dose-ranging study, it is designed for signal detection rather than establishing a gold standard.
- Strengths: Methodological rigor in dose exploration; high correlation with patient satisfaction metrics.
- Limitations: Limited sample size, lack of long-term durability data, and potential for variability in injection technique.
Note: Optimal dosing and standardized injection patterns for reproducible, "real-world" results remain undefined.
š©ŗ Practice Recommendation
Status Label: [Investigational Only]
Monday Morning Action: Maintain current standards of care. Do not adopt OnabotulinumtoxinA for platysma prominence as a routine clinical protocol based solely on this data.
- Monitor: Await Phase 3 data to confirm safety profiles and establish standardized injection units per band.
- Educate: If patients inquire about "the Botox neck lift," acknowledge the emerging data but clarify that the specific protocol for platysma prominence is currently under investigation.